Literature DB >> 2833452

The effects of human recombinant tumor necrosis factor on glioma-derived cell lines: cellular proliferation, cytotoxicity, morphological and radioreceptor studies.

J T Rutka1, J R Giblin, M E Berens, E Bar-Shiva, K Tokuda, J R McCulloch, M L Rosenblum, T E Eessalu, B B Aggarwal, W J Bodell.   

Abstract

To determine whether tumor necrosis factor is of potential value for the treatment of human malignant gliomas, we studied the effects of human recombinant tumor necrosis factor (rTNF-alpha) on the morphology, incorporation of tritiated thymidine, and proliferation of 5 established cell lines derived from human malignant gliomas and 3 normal human brain cell cultures. A radioreceptor analysis for rTNF-alpha was performed on all cell lines and cultures. Two of the 5 human glioma cell lines (SF-188 and U 343 MG-A) demonstrated a marked decrease (60% or less of untreated controls) in the uptake of tritiated thymidine when treated with rTNF-alpha at a concentration of 40 U/ml; rTNF-alpha at 100 U/ml had antiproliferative and cytotoxic effects on both cell lines. The growth and proliferation of cell lines SF-126 and U 251 MG were not affected by rTNF-alpha even at high concentrations (5,000 U/ml). The growth and proliferation of SF-539 were affected to an intermediate degree. A colony-forming efficiency assay corroborated the results of the proliferation studies: SF-126 was relatively resistant (surviving fraction of 0.9 at 500 U/ml) and SF-188 was relatively sensitive (surviving fraction of 0.08 at 500 U/ml) to the cytotoxic effects of rTNF-alpha. Time-sequence electron microscopy showed that rTNF-alpha at a concentration of 500 U/ml caused ultrastructural changes in SF-188, including increased intracytoplasmic vesiculation, swelling and degeneration of mitochondria, loss of cell:cell junctional complexes, and fragmentation of the plasma membrane. Studies with 125I-rTNF-alpha showed a variable degree of binding in all cell lines and cultures. SF-188, a highly sensitive cell line, demonstrated the strongest binding of 125I-rTNF-alpha (3,400 receptors/cell with high affinity; kd = 0.27 nM), while SF-126, a highly resistant cell line, had the weakest binding (809 receptors/cell; kd = 0.25 nM). We conclude that there is a spectrum of antiproliferative and cytotoxic activity among glioma-derived tumor cell lines exposed to rTNF-alpha. An increased number of rTNF-alpha receptors appears to be a necessary but insufficient condition to explain the antiproliferative effects observed in some glioma-derived cell lines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833452     DOI: 10.1002/ijc.2910410417

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection.

Authors:  C M Mastroianni; F Paoletti; C Valenti; V Vullo; E Jirillo; S Delia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

2.  Enhancement of epidermal growth factor receptor expression on glioma cells by recombinant tumor necrosis factor alpha.

Authors:  K Adachi; P Belser; H Bender; D Li; U Rodeck; E N Benveniste; D Woo; W H Schmiegel; D Herlyn
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Acute effects of human recombinant tumor necrosis factor-alpha on the cerebral vasculature of the rat in both normal brain and in an experimental glioma model.

Authors:  G Kido; J L Wright; R E Merchant
Journal:  J Neurooncol       Date:  1991-04       Impact factor: 4.130

Review 4.  Neurologic and psychiatric manifestations of HIV disease.

Authors:  H Hollander
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  Responses of human glioblastoma cells to human natural tumor necrosis factor-alpha: susceptibility, mechanism of resistance and cytokine production studies.

Authors:  S Sakuma; Y Sawamura; M Tada; T Aida; H Abe; K Suzuki; N Taniguchi
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

7.  Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas.

Authors:  M Tada; Y Sawamura; S Sakuma; K Suzuki; H Ohta; T Aida; H Abe
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Growth-inhibiting effect of intratumoral recombinant human tumor necrosis factor on an experimental model of primitive neuroectodermal tumor.

Authors:  J Vaquero; M Zurita; S Oya
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  TNF-induced signaling in apoptosis.

Authors:  P C Rath; B B Aggarwal
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.542

10.  Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha.

Authors:  R Engers; F van Roy; T Heymer; U Ramp; R Moll; M Dienst; U Friebe; A Pohl; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.